CoChat

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma and non-small cell lung cancer (NSCLC). Despite important clinical benefits, these therapies are associated with a diverse spectrum of immune-related adverse events (irAEs) that are typically transient, but occasionally severe or even fatal. CASE PRESENTATION: This autopsy case illustrates that clinically overt irAEs may represent only a fraction of the total spectrum of immune-related organ pathology in patients treated with immune checkpoint inhibitors. We report a comprehensive analysis of systemic irAE pathology based on the autopsy of a 35-year-old female patient with metastatic melanoma treated first with ipilimumab and then nivolumab. The clinical course was characterized by a mixed tumor response with regression of skin and lung metastases and fatal progression of metastatic disease in the small bowel, peritoneum and brain. During therapy with ipilimumab, radiographic features of immune-related pneumonitis were noted. The autopsy examination established a sarcoid-like granulomatous reaction of the lung, pulmonary fibrosis and diffuse alveolar damage. Importantly, a clinically unapparent but histologically striking systemic inflammation involving the heart, central nervous system, liver and bone marrow was identified. Severe immune-related end-organ damage due to lymphocytic myocarditis was found. CONCLUSIONS: Autopsy studies are an important measure of quality control and may identify clinically unapparent irAEs in patients treated with immunotherapy. Pathologists and clinicians need to be aware of the broad spectrum of irAEs for timely management of treatment-related morbidity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-016-0117-1

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Time axis. Line graph illustrating disease progression and therapeutic intervention between initial diagnosis in August 2012 and death from metastatic melanoma in September 2015
Fig. 1 Time axis. Line graph illustrating disease progression and therapeutic intervention between initial diagnosis in August 2012 and death from metastatic melanoma in September 2015CC BY · PubMed Central
Fig. 2 Morphological progression from initial diagnosis. a Melanoma ex naevo (08/2012) b local recurrence (08/2013) with deep in transit metastasis and c sentinel node metastasis d skin metastasis (10/2014) e dedifferentiated melanoma at autopsy f intratumoral CD8-positive T-cell infiltrates at autopsy as detected by immunohistochemistry; scale bars as indicated
Fig. 2 Morphological progression from initial diagnosis. a Melanoma ex naevo (08/2012) b local recurrence (08/2013) with deep in transit metastasis and c sentinel node metastasis d skin metastasis (10/2014) e dedifferentiated melanoma at autopsy f intratumoral CD8-positive T-cell infiltrates at autopsy as detected by immunohistochemistry; scale bars as indicatedCC BY · PubMed Central
Fig. 3 Lung damage patterns. a CT Thorax: Pulmonary metastasis before therapy with Ipilimumab (02/2015) b CT Thorax: pulmonary metastasis regression, ground glass opacities after Ipilimumab (04/2015) c sarcoid-like reaction d elastica stain showing epithelioid granulomas surrounded by fibrotic rings e CD8-positive T-cell infiltrates surrounding giant cell granulomas as detected by immunohistochemistry f diffuse alveolar damage; scale bars as indicated
Fig. 3 Lung damage patterns. a CT Thorax: Pulmonary metastasis before therapy with Ipilimumab (02/2015) b CT Thorax: pulmonary metastasis regression, ground glass opacities after Ipilimumab (04/2015) c sarcoid-like reaction d elastica stain showing epithelioid granulomas surrounded by fibrotic rings e CD8-positive T-cell infiltrates surrounding giant cell granulomas as detected by immunohistochemistry f diffuse alveolar damage; scale bars as indicatedCC BY · PubMed Central
Fig. 4 Lymphocytic myocarditis and hepatic T-cell infiltration. a Normal-sized heart with normal coronary arteries in frontal view b patchy myocardial fibrosis and mononuclear infiltrates c myocardial CD8-positive T-cell infiltrates as detected by immunohistochemistry e mild hepatic portal T-cell infiltrates f lobular hepatic CD8-positive T-cell infiltrates and g sinusoidal infiltration by CD68+ histiocytic as detected by immunohistochemistry; scale bars as indicated
Fig. 4 Lymphocytic myocarditis and hepatic T-cell infiltration. a Normal-sized heart with normal coronary arteries in frontal view b patchy myocardial fibrosis and mononuclear infiltrates c myocardial CD8-positive T-cell infiltrates as detected by immunohistochemistry e mild hepatic portal T-cell infiltrates f lobular hepatic CD8-positive T-cell infiltrates and g sinusoidal infiltration by CD68+ histiocytic as detected by immunohistochemistry; scale bars as indicatedCC BY · PubMed Central
Fig. 5 Meningoencephalitis and bone marrow lymphocytosis. a Meningeal lymphocytosis with b a predominantly CD8+ T-cell infiltrate as demonstrated by immunohistochemistry and c extension into the brain parenchyma; d Hypercellular bone marrow with e an increase in CD3+ and f CD8+ T-lymphocytes as detected by immunohistochemistry; scale bars as indicated
Fig. 5 Meningoencephalitis and bone marrow lymphocytosis. a Meningeal lymphocytosis with b a predominantly CD8+ T-cell infiltrate as demonstrated by immunohistochemistry and c extension into the brain parenchyma; d Hypercellular bone marrow with e an increase in CD3+ and f CD8+ T-lymphocytes as detected by immunohistochemistry; scale bars as indicatedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

    Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845

  • Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

    Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

    Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 2×

    “A non-infectious myocarditis in patients treated with nivolumab [3, 29] and ipilimumab [4] has been previously described, but biopsy studies are rare.”
    Background
  • Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

    Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×

    “Immune checkpoint inhibitors interacting with the PD-1/PD-L1 axis were recently approved by the Food and Drug Administration (FDA) based on successful large randomized controlled clinical trials [2] of patients with metastatic melanoma [3, 4], non-small cell lung cancer (NSCLC) [5, 6] and renal cell cancer [7].”
    Background
  • PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

    Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

  • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×

    “Immune checkpoint inhibitors interacting with the PD-1/PD-L1 axis were recently approved by the Food and Drug Administration (FDA) based on successful large randomized controlled clinical trials [2] of patients with metastatic melanoma [3, 4], non-small cell lung cancer (NSCLC) [5, 6] and renal cell cancer [7].”
    BackgroundInfluential
  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

    Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 3×

    “Immune checkpoint inhibitors interacting with the PD-1/PD-L1 axis were recently approved by the Food and Drug Administration (FDA) based on successful large randomized controlled clinical trials [2] of patients with metastatic melanoma [3, 4], non-small cell lung cancer (NSCLC) [5, 6] and renal cell cancer [7].”
    BackgroundInfluential
  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×

    “Immune checkpoint inhibitors interacting with the PD-1/PD-L1 axis were recently approved by the Food and Drug Administration (FDA) based on successful large randomized controlled clinical trials [2] of patients with metastatic melanoma [3, 4], non-small cell lung cancer (NSCLC) [5, 6] and renal cell cancer [7].”
    Background
  • Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×

    “A non-infectious myocarditis in patients treated with nivolumab [3, 29] and ipilimumab [4] has been previously described, but biopsy studies are rare.”
    Background
  • Cancer immunotherapy comes of age

    Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×

    “Four years after the approval of the first checkpoint inhibitor ipilimumab (anti-CTLA-4) for advanced melanoma in 2011, cancer immunotherapy is now considered one of the pillars of cancer therapy [1].”
    Background

Show all 31 references

Cited by

See all 201

Metadata

Authors
Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D.
Affiliations
  • University of Bern (CH)
  • University Hospital of Basel (CH)
  • Kantonsspital Baselland (CH)
Corresponding author
Mertz, Kirsten D.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2016-03-15
Volume
4
Issue
1
Pages
13-13
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2301851804
Cited by
200
References
31
Citations by year
2026: 6 · 2025: 9 · 2024: 12 · 2023: 15 · 2022: 19 · 2021: 26 · 2020: 27 · 2019: 21 · 2018: 25 · 2017: 31 · 2016: 9
FWCI
15.64
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoidosis and Beryllium Toxicity Research
Keywords
immune-related adverse events, immune checkpoint inhibitors, metastatic melanoma, ipilimumab, nivolumab, CTLA-4, PD-1, lymphocytic myocarditis, immune-related pneumonitis, pulmonary fibrosis, diffuse alveolar damage, systemic inflammation, autopsy findings, immunotherapy toxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. https://app.cochat.ai/papers/10.1186/s40425-016-0117-1
The paper
Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016). Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-016-0117-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.